DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Lip GY, Keshishian A, Kamble S. , et al.
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Thromb Haemost 2016;
116 (05) 975-986
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.